Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial

IMPORTANCE: Based on a small retrospective study, rechallenge with cetuximab-based therapy for patients with KRAS wild-type metastatic colorectal cancer (mCRC) who were previously treated with the same anti–epidermal growth factor receptor–based regimen might be efficacious. Recent data suggest the...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :JAMA Oncol
Главные авторы: Cremolini, Chiara, Rossini, Daniele, Dell’Aquila, Emanuela, Lonardi, Sara, Conca, Elena, Del Re, Marzia, Busico, Adele, Pietrantonio, Filippo, Danesi, Romano, Aprile, Giuseppe, Tamburini, Emiliano, Barone, Carlo, Masi, Gianluca, Pantano, Francesco, Pucci, Francesca, Corsi, Domenico C., Pella, Nicoletta, Bergamo, Francesca, Rofi, Eleonora, Barbara, Cecilia, Falcone, Alfredo, Santini, Daniele
Формат: Artigo
Язык:Inglês
Опубликовано: American Medical Association 2018
Предметы:
Original Investigation
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6439839/
https://ncbi.nlm.nih.gov/pubmed/30476968
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2018.5080
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы